In a phase 3 RCT of 343 patients with recurrent grade 3 astrocytoma, eflornithine plus lomustine vs lomustine alone did not improve overall survival (median 23.4 vs 20.3 months; HR 0.94); grade 3+ myelosuppression (42% vs 29%) and hearing loss (24% vs 0%) were higher.
RCTn = 343
Colman et al. STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma